Stalls Rovirosa FCPA Appeal, Seeks 30 More Days
DOJ filed a notice of appeal in the Rovirosa FCPA acquittal case, then admitted the Solicitor General hasn't decided if it wants one.
Morning Brief — July 4, 2026. AstraZeneca's fourth deal with Chinese partner CSPC since 2024 signals a disciplined, milestone-heavy dealmaking playbook: small upfront checks controlling outsized potential. Today's brief tracks what that structure means for cross-border biotech licensing.
AstraZeneca paid CSPC just $30M upfront to secure rights worth up to $1.77B in kidney-drug milestones — marking the fourth partnership check the company has written to the Chinese drugmaker since 2024.
DOJ filed a notice of appeal in the Rovirosa FCPA acquittal case, then admitted the Solicitor General hasn't decided if it wants one.
AstraZeneca puts just $30M down now to control up to $1.77B in kidney-drug milestones, its fourth check written to Chinese partner CSPC since 2024.
A spyware investigator got spied on by the exact tool he was investigating. It's a live case study in why patch cadence isn't a security strategy.
Kraken's parent paid up to $600M for a Hong Kong payments firm — here's what Payward actually bought, and why the discount to Stripe's Bridge deal.
NJ's grocery pricing ban carries real Consumer Fraud Act penalties, not a warning letter, and it's one of several states moving this year.
A House China Committee letter gives Eli Lilly until July 17 to explain trials run inside Chinese military hospitals and Xinjiang.
FBI and IRS-CI seize NetNut's domains over a 2-million-device botnet. Owner Alarum is a Nasdaq-listed company, not an anonymous darknet outfit.
He flaunted diamond chains and Paris hotels online while still a minor. Now, at 19, the Scattered Spider hacker faces federal charges in Chicago.
Alibaba and Ant's AUS unit just bought their way out of a drug-trafficking case, $600M split between two penalty-forfeiture structures.
No share price, no premium to measure. Just a binary bet: $227M upfront now, up to $796M if potravitug clears its kidney-transplant trial.
Sanofi's Genzyme unit racked up its second FDA warning letter in under two years, this time tied to hemophilia drug Altuviiio and Thymoglobulin.
A Nevada federal judge slashed the FTC's $52.9M ask to $6.5M, but still found Cliq in contempt for years of dodging a 2015 anti-fraud order.
EagleBank's compliance team flagged a check-kiting scheme in 2008. Executives overrode them anyway, and it cost $9.7M to make the DOJ go away.
Anthropic just traded engineering headcount and early model access for a lifted US export ban, a template AI compliance teams should study.
House Financial Services just voted to define wage-access fees as not-loans, pulling the rug from under every state AG's payday-lending case.
A federal lending program built to rescue small businesses now owes taxpayers an answer: why is a third of its $16.6B book underwater?
JPMorgan wants a federal judge to erase the $4.2 million award a FINRA panel gave a broker fired over a $642 deli platter ordered for absent clients.
AstraZeneca just became Ken Paxton's latest pharma kickback target, paying nearly $34M for 'free nurses' without admitting wrongdoing.
Atom Bank's £600M auction couldn't find a full-price buyer, and shareholders are now weighing whether management should pay the price.
The SAFE Banking Act has cleared the House seven times without a Senate vote. Cannabis reclassification may finally change that math.